Literature DB >> 27142125

Incontinence: Adding mirabegron to solifenacin improves patient outcomes.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27142125     DOI： 10.1038/nrurol.2016.86

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).

Authors:  Marcus J Drake; Christopher Chapple; Ahmet A Esen; Stavros Athanasiou; Javier Cambronero; David Mitcheson; Sender Herschorn; Tahir Saleem; Moses Huang; Emad Siddiqui; Matthias Stölzel; Claire Herholdt; Scott MacDiarmid
Journal:  Eur Urol       Date:  2016-03-08       Impact factor: 20.096

2.  Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].

Authors:  Scott MacDiarmid; Salman Al-Shukri; Jack Barkin; Aino Fianu-Jonasson; Philippe Grise; Sender Herschorn; Tahir Saleem; Moses Huang; Emad Siddiqui; Matthias Stölzel; Claire Hemsted; Jameel Nazir; Zalmai Hakimi; Marcus J Drake
Journal:  J Urol       Date:  2016-04-08       Impact factor: 7.450
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.